Lacy Tangedahl
Family · Billings, MTNPI 1942501861
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,659 of the $31,276 with a category attached, or 94.8%. AbbVie accounts for 96.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $25,234 and has fallen 98.7% since, to $319 in 2025. Among family clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $613.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Astellas Pharma US Inc$389
- Johnson & Johnson$221
- Merck$125
- Sanofi$125
- Edwards Lifesciences$114
- plus $207 from 8 others
What the payments were for
- Speaking & faculty fees$29,65995%
- Food & beverage$1,0833%
- Education$5342%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 28 | $30,095 |
| Astellas Pharma US Inc | 4 | $389 |
| Johnson & Johnson | 2 | $221 |
| Merck | 6 | $125 |
| Sanofi | 1 | $125 |
| Edwards Lifesciences | 1 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Seagen Inc. | 1 | $47 |
| AstraZeneca | 1 | $34 |
| Foundation Medicine, Inc. | 1 | $17 |
| GSK | 1 | $15 |
| Novartis | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,276 in reported general payments places this provider in the 95th percentile of 481 family providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 53 | $752,983 |
| XtandiEnzalutamide | 39 | $508,096 |
| PomalystPomalidomide | 22 | $485,196 |
| ImbruvicaIbrutinib | 31 | $406,282 |
| ErleadaApalutamide | 26 | $370,574 |
| CalquenceAcalabrutinib Maleate | 24 | $358,601 |
| VenclextaVenetoclax | 25 | $357,145 |
| IbrancePalbociclib | 22 | $345,427 |
| KisqaliRibociclib Succinate | 20 | $327,054 |
| RevlimidLenalidomide | 15 | $287,455 |
| TagrissoOsimertinib Mesylate | 13 | $208,831 |
| Abiraterone Acetate | 105 | $206,162 |
| BrukinsaZanubrutinib | 12 | $153,131 |
| Pazopanib Hcl | 16 | $138,008 |
| PromactaEltrombopag Olamine | 18 | $117,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence, Tagrisso | $34 | $567,43337 claims |
| Astellas Pharma US IncXtandi | $389 | $508,09639 claims |
| NovartisKisqali, Promacta | $15 | $445,05038 claims |
| Johnson & JohnsonErleada, Xarelto | $221 | $402,24663 claims |
| PfizerIbrance, Eliquis | $14 | $358,32537 claims |
| AbbVieVenclexta | $30,095 | $357,14525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 family providers in Montana.
Other family in Billings
- Wendy DonaughBillings$3K
- Payton O'TooleBillings$3K
- Laura SmithBillings$3K
- Christina RicheyBillings$3K
- Kami WinnickiBillings$2K
- Taylor RicheyBillings$2K
- Amanda MurrayGreat Falls$101K
- Kara AddisonHelena$50K
- Mara ZelloBozeman$31K
- Michelle Weaver KnowlesMissoula$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.